论文部分内容阅读
[目的]观察恩替卡韦(ETV)联合苦参素治疗HBeAg阳性慢性乙型肝炎(CHB)的疗效。[方法]92例HBeAg阳性CHB患者随机分为2组,治疗组48例,每天服用ETV 0.5 mg,苦参素片0.6 g;对照组44例,每天服用ETV 0.5 mg。分别观察服药12、24、48周时的治疗效果。[结果]对照组和治疗组在12、24、48周的HBV DNA阴转率分别为29.55%、40.91%、63.64%和43.75%、58.33%、83.33%,2组比较在12、24周时差异无统计学意义(P>0.05),而在48周时差异有统计学意义(P<0.05)。对照组和治疗组的HBeAg转阴率,在12、24周时分别为36.37%、43.75%和50.00%、64.59%,2组比较P>0.05,而在48周时分别为59.09%和81.25%(P<0.05)。对照组和治疗组的HBeAg/HBeAb血清转换率,12、24周时分别为29.55%、37.50%和40.91%、52.09%,2组比较P>0.05,而在48周时分别为47.73%和68.75%,差异有统计学意义(P<0.05)。[结论]ETV联合苦参素治疗CHB可明显提高抗病毒治疗效果。
[Objective] To observe the efficacy of entecavir (ETV) and oxymatrine in the treatment of HBeAg-positive chronic hepatitis B (CHB). [Method] Ninety-two patients with HBeAg-positive CHB were randomly divided into two groups. The treatment group received 48 mg of ETV 0.5 mg per day and 0.6 g of matrine tablets. The control group received ETV 0.5 mg daily. The effects of treatment were observed at 12, 24 and 48 weeks respectively. [Results] The negative conversion rates of HBV DNA in control group and treatment group at 12, 24 and 48 weeks were 29.55%, 40.91%, 63.64% and 43.75%, 58.33% and 83.33% respectively. The difference was not statistically significant (P> 0.05), but the difference was statistically significant at 48 weeks (P <0.05). The negative rate of HBeAg in control group and treatment group were 36.37%, 43.75% and 50.00%, 64.59% respectively at 12 and 24 weeks, P> 0.05 in two groups and 59.09% and 81.25% respectively at 48 weeks (P <0.05). The HBeAg / HBeAb seroconversion rates of the control group and the treatment group were 29.55%, 37.50% and 40.91%, 52.09% at 12 and 24 weeks respectively, P> 0.05 in the two groups and 47.73% and 68.75 at 48 weeks respectively %, The difference was statistically significant (P <0.05). [Conclusion] ETV combined with oxymatrine treatment of CHB can significantly improve the effect of antiviral therapy.